Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer

Corticosteroid switching can reverse abiraterone resistance in some patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we investigated the potential biomarkers for predicting the efficacy of corticosteroid switching during treatment with abiraterone acetate (AA). We retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Yu-Chao, Zhao, Jin-Ge, Zhang, Meng-Ni, Zhang, Yi-Jun, Yang, Zhen-Yu, Chen, Ni, Chen, Jun-Ru, Shen, Peng-Fei, Sun, Guang-Xi, Zhang, Xing-Ming, Li, Yong-Hong, Zeng, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887097/
https://www.ncbi.nlm.nih.gov/pubmed/34380864
http://dx.doi.org/10.4103/aja202143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887097/
https://www.ncbi.nlm.nih.gov/pubmed/34380864
http://dx.doi.org/10.4103/aja202143

Ejemplares similares